Navigation Links
Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation!
Date:9/14/2009

JOHNSON CITY, Tenn., Sept. 14 /PRNewswire/ -- RxBio, Inc., announces that its lead product, Rx100, a potent radioprotectant as well as radiomitigator, protects against lethal, whole-body radiation when administered before, during, or up to 72 hours after exposure.

In recent experiments, the efficacy of Rx100 was tested by treating with a single subcutaneous dose at either 48 or 72 hours after lethal, whole-body gamma irradiation. Results at both time points were essentially identical and only slightly lower than what had been seen when the drug was administered at 24-26 hours after radiation exposure.

Continued extensive testing of Rx100 proves its unique properties in comparison to other drug candidates in the pipeline. Of significance is the fact that Rx100: a) is a small molecule, b) is essentially nontoxic at therapeutic doses, c) has a long shelf life, d) is nonimmunogenic, e) and provides effective treatment of ARS when administered up to three days after injury. There are no other small-molecule radiomitigators described in the scientific literature as effective as Rx100.

Dr. W. Shannon McCool, RxBio's CEO, points out that: "Rx100 is unique among radioprotectants / radiomitigators in that it boosts natural mechanisms that promote and sustain cell survival in almost every cell type and at the same time inhibits the cascade leading to programmed cell death (apoptosis). Thus, Rx100 augments the good and shuts down the bad. While other products shut down essential cellular signaling mechanisms involved in radiation-induced cellular injury and tend to lack specificity and/or may be toxic, Rx100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival and antiapoptosis. Among its actions, Rx100 protects critical stem cells. Rx100 can be formulated for a wide range of patient types--from infants to the elderly - and can be administered either orally or subcutaneously."

In addition, Dr. Gabor Tigyi, RxBio's CSO, comments that: "Rx100 is a potent protector of the GI tract. This drug provides significant protection to the gut from radiation as well as other toxic substances such as cholera toxin. Among its actions, Rx100 maintains the mucosal barrier of the GI tract. It prevents severe diarrhea and the entry of bacterial toxins into the blood stream - both potentially severe side effects."

Several agencies of the Federal Government continue their interest and support in this promising new compound and its unique approach and mechanism.


'/>"/>
SOURCE RxBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
2. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
3. Millstone Medical Outsourcing Relocates Memphis Distribution Center Within 72 Hours of Tornado Disaster
4. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
5. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
6. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
8. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
9. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
10. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
11. Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... ... avoid the lengthy trial and error process by finding the right antidepressant faster. ... also strengthen the doctor-patient relationship through a personalized approach to treatment. ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science ... technologies ripe for commercialization, and who are affiliated with the 21 partner academic ... proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept program ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has ... Challenge is a two-hour team-building package designed for groups of 10-30 people. ... Abel, which include items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls ...
(Date:5/18/2017)... ... ... NDA Partners Chairman Carl Peck, MD , announced today that Richard ... of Pharmaceutical Development Business Unit of Cardinal Health, has joined the firm as an ... former Chief Operating Officer at Anaborex, Senior VP and General Manager of the San ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):